Ocular Therapeutix

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Ocular Therapeutix headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device sector. The company focuses on Biotechnology and has secured $102.5B in funding across 144 round(s). With a team of 251-500 employees, Ocular Therapeutix is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Ocular Therapeutix, raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.